Forget cash ISAs! At 4.4% dividend yield, I’ll buy this FTSE 100 stock

GSK is delivering a 4.4% dividend yield. That’s more than double what you would get from a cash ISA.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

GlaxoSmithKline (LSE: GSK) has a market capitalisation of over £90 billion, making it one of the 10 largest companies listed on the London Stock Exchange. Since its founding in 2000, from the merger of Glaxo Wellcome and SmithKline Beecham, the company has been returning real value to its shareholders.

GSK has been regularly paying dividends for years. In fact, its annual payment has consistently grown at a compounded annual growth rate of roughly 3.4% over the past 10 years. Last year, the pharmaceutical giant yielded 4.4% in dividends. I believe these characteristics make it ideal for income investors.

In comparison, a good easy-access cash ISA may give you returns of 2%. I don’t know about you, but I know where I would invest my money.

A strong business base

GSK’s business base is strong. Consider the fact that the company has succeeded in diversifying its revenue sources over the years. Apart from pharmaceuticals, GSK is into vaccines and healthcare consumer products, too.

Moreover, what is interesting is the huge commitment that the company has been showing towards research and development (R&D). In fact, currently it is reinvesting much of its cash flow into that. GSK spends close to £4 billion on R&D every year to remain relevant in the industry and develop a competitive edge.

Consequently, if there is a pharmaceutical company that will keep its place in the coming years, I believe it is GSK.

Investment in GSK is for the long haul

GSK has found itself in troubled waters in recent years. For the past five years, earnings per share (EPS) have been rapidly falling. The company has been investing heavily in R&D to update its pipeline of drugs.

Last year the stock price delivered almost 30% in return. Its R&D investments are for the intermediate to long term, so only patient investors will gain I believe.

Why I’m a buyer

GSK is a solid income stock. The drug company currently has a stunning 4.4% dividend yield. For years its annual payout has been roughly 61% and as much as 89%. Hence, apart from its declining EPS concern, GSK easily makes my watchlist.

But what about the declining EPS? The first cause is increasing competition. For example, in 2019 GSK had its Advair – a bronchodilator used to prevent symptoms of asthma and chronic obstructive pulmonary disease – challenged by the approval of a generic competitor in the U.S.

Next is its heavy investment in building its products portfolio. In December 2018, for instance, it started the acquisition of Tesaro, an oncology-focused pharmaceutical firm, for $5.1 billion.

Apart from these, the past years have actually been good for GSK. Therefore, the company’s falling EPS should not be a concern at all. And 4.4% is a lot better than 2%, don’t you think?

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Pi De Jonge has no position in any of the shares mentioned but will be opening long positions in the future. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Here’s how I’d follow Warren Buffett to start building passive income in 2025

Ben McPoland highlights one FTSE 250 firm with a strong competitive edge that he thinks can continue rewarding investors with…

Read more »

Investing Articles

Burberry shares: undervalued FTSE gems that are ready to rocket?

Burberry shares soared at the beginning of the week as the takeover rumour mill went into overdrive. Is Paul Summers…

Read more »

US Stock

Here are the latest share price forecasts for S&P 500 giant Amazon

Amazon has generated monster gains for investors over the last decade. And Wall Street analysts believe the S&P 500 stock…

Read more »

Man writing 'now' having crossed out 'later', 'tomorrow' and 'next week'
Investing Articles

2 high-yield FTSE 250 shares I’d buy today — and 1 that I’d avoid

UK markets have felt some volatility after last week’s Budget and the FTSE 250 was no stranger to it. Our…

Read more »

Investing Articles

3 reasons the Rolls-Royce share price could soar over the next decade

Sustainable aviation fuel, narrow-body aircraft, and small nuclear reactors could all keep the Rolls-Royce share price climbing over the next…

Read more »

British flag, Big Ben, Houses of Parliament and British flag composition
Investing Articles

Here’s how much income I’d get if I invested my entire £20k ISA in cheap BT shares

BT shares are on the up but still cheap, while the FTSE 100 telecoms stock offers a good yield too.…

Read more »

Investing Articles

2 FTSE dividend shares yielding more than 6% with P/Es of less than 9!

Harvey Jones picks out two brilliant FTSE 100 dividend shares that yield more than 6% but are selling at strangely…

Read more »

Investing Articles

Up 105% in a year! Is this rocketing FTSE bank the perfect pick for my Stocks and Shares ISA?

Harvey Jones is drawing up a shortlist of stocks to purchase inside his Stocks and Shares ISA allowance. This FTSE…

Read more »